Tag Archives: Andrew Fein

H.C. Wainwright Remains a Buy on Translate Bio Inc (TBIO)

In a report released today, Andrew Fein from H.C. Wainwright maintained a Buy rating on Translate Bio Inc (TBIO – Research Report), with a price target of $21. The company’s shares closed yesterday at $13.12. Fein wrote: “Valuation and risks

H.C. Wainwright Believes Insmed (NASDAQ: INSM) Won’t Stop Here

H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Insmed (INSM – Research Report) today and set a price target of $52. The company’s shares closed yesterday at $31.30, close to its 52-week high of $32.16. Fein observed: “Our

Analysts Are Bullish on These Healthcare Stocks: Amarin (AMRN), Aileron Therapeutics Inc (ALRN)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amarin (AMRN – Research Report), Aileron Therapeutics Inc (ALRN – Research Report) and Durect Corp (DRRX – Research Report) with bullish sentiments.

Seattle Genetics (SGEN) Received its Third Buy in a Row

After Barclays and RBC Capital gave Seattle Genetics (NASDAQ: SGEN) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Seattle Genetics today and set a price

H.C. Wainwright Reiterates a Buy Rating on Unum Therapeutics Inc (UMRX)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Unum Therapeutics Inc (UMRX – Research Report), with a price target of $18. The company’s shares closed yesterday at $4.41, close to its 52-week low

Strongbridge Biopharma Plc (SBBP) Received its Third Buy in a Row

After Cantor Fitzgerald and Oppenheimer gave Strongbridge Biopharma Plc (NASDAQ: SBBP) a Buy rating last month, the company received another Buy, this time from H.C. Wainwright. Analyst Andrew Fein maintained a Buy rating on Strongbridge Biopharma Plc today and set